Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. BBI Life Sciences Corporation
  6. News
  7. Summary
    1035   KYG1089Y1180

BBI LIFE SCIENCES CORPORATION

(1035)
End-of-day quote Hong Kong Stock Exchange  -  2020-05-11
3.490 HKD   +0.87%
2020LJ Future Ltd completed the acquisition of 43.3% stake in BBI Life Sciences Corporation.
CI
2020BBI Life Sciences Corporation Appoints Liu Bin as a Non-Executive Director, Effective April 18, 2020
CI
2020BBI Life Sciences Corporation Did Not Recommend the Payment of A Final Dividend for the Year Ended December 31, 2019
CI
SummaryChartsNewsCompanyFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

LJ Future Ltd completed the acquisition of 43.3% stake in BBI Life Sciences Corporation.

06/04/2020 EST

LJ Future Ltd made a proposal to acquire 43.3% stake in BBI Life Sciences Corporation (SEHK:1035) for approximately HKD 850 million on January 14, 2020. LJ Future Ltd will pay for HKD 3.5 per share for around 242.7 million shares of BBI Life Sciences. As of April 17, 2020, the scheme of arrangement put out by BBI Life Sciences states that if the scheme of arrangement becomes effective the scheme shares will be cancelled on June 8, 2020 and extinguished in exchange for the cancellation price of HKD 3.5 in cash for every scheme share. As of March 4, 2020, a total of 0.05 million shares were allotted and issued as a result of the exercise of 0.05 million options in aggregate, each relation to one share. LJ intends to finance the entire cash amount required to implement the Proposal from a loan facility in the amount of up to HKD 900 million provided by CMB. BBI Life Sciences Corporation will be delisted on June 8, 2020. The offer is conditional upon conditions, inter alia, the Scheme is approved (by way of poll) by the shareholders of BBI Life Sciences Corporation and approval from court. Transaction was approved by shareholders of BBI Life Sciences Corporation on May 11, 2020. Court hearing of the petition to sanction the Scheme will be held on May 29, 2020. On May 29, 2020, the Grand Court approved the transaction without modifications. The scheme will not become effective before June 1, 2020. The effective date of the scheme is June 4, 2020. Optima Capital was appointed as the financial advisor to the Board of BBI Life Sciences. Haitong International Securities Group Limited acted as a financial advisor to LJ Future. Bernadette Chen of Conyers Dill & Pearman, Hong Kong Office and Ben Hobden of Conyers Dill & Pearman (Cayman) Limited acted as the legal advisor for BBI Life. LJ Future Ltd completed the acquisition of 43.3% stake in BBI Life Sciences Corporation (SEHK:1035) on June 4, 2020. All conditions have been fulfilled.


ę S&P Capital IQ 2020
All news about BBI LIFE SCIENCES CORPORATION
2020LJ Future Ltd completed the acquisition of 43.3% stake in BBI Life Sciences Corporation..
CI
2020BBI Life Sciences Corporation Appoints Liu Bin as a Non-Executive Director, Effective A..
CI
2020BBI Life Sciences Corporation Did Not Recommend the Payment of A Final Dividend for the..
CI
2020Bbi Life Sciences Corporation Reports Earnings Results for the Full Year Ended December..
CI
2020LJ Future Ltd made a proposal to acquire 43.3% stake in BBI Life Sciences Corporation f..
CI
2019Bbi Life Sciences Corporation Reports Earnings Results for the Half Year Ended June 30,..
CI
2019BBI Life Sciences Corporation Recommends Final Dividend for the Year Ended December 31,..
CI
2019Bbi Life Sciences Corporation Reports Earnings Results for the Full Year Ended December..
CI
2018BBI Life Sciences Corporation Announces Unaudited Consolidated Earnings Results for the..
CI
2018BBI Life Sciences Corporation Provides Group Profit Guidance for the Six Months Ended J..
CI
More news
Chart BBI LIFE SCIENCES CORPORATION
Duration : Period :
BBI Life Sciences Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Managers and Directors
Luo Jia Wang Chief Executive Officer & Executive Director
Jin Wang President & Executive Director
Xiao Lei Gu Chief Financial Officer
Qi Song Wang Chairman
Jian Jun Liu Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
BBI LIFE SCIENCES CORPORATION43.62%252
MODERNA, INC.-30.55%67 769
IQVIA HOLDINGS INC.-22.03%40 859
LONZA GROUP AG-33.93%39 445
ALNYLAM PHARMACEUTICALS, INC.25.44%26 171
SEAGEN INC.-20.16%22 918